Cited by 254Antifungal resistance and susceptibilityFungal Infections and StudiesHIV/AIDS oral health manifestations

The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.

Randomized, Double-Blind, Multicenter Study of Caspofungin versus Amphotericin B for Treatment of Oropharyngeal and Esophageal Candidiases

Open access

Arathoon, Eduardo G., Gotuzzo, Eduardo, Noriega, L. Miguel, Berman, Rayanne S., DiNubile, Mark J., Sable, Carole A.·2002·Antimicrobial Agents and Chemotherapy

DOI 10.1128/aac.46.2.451-457.2002PMC PMC127070

Open this paper in CoChat — free account

Abstract

Caspofungin is an antifungal agent of the novel echinocandin class. We investigated its efficacy, safety, and tolerability as therapy for oropharyngeal and/or esophageal candidiasis in a phase II dose-ranging study. Patients were randomized in a double-blind manner to receive either caspofungin acetate (35, 50, or 70 mg) or amphotericin B (0.5 mg/kg of body weight) intravenously once daily for 7 to 14 days. A favorable response required both complete resolution of symptoms and quantifiable improvement of mucosal lesions 3 to 4 days after discontinuation of study drug. Efficacy was assessed using a modified intent-to-treat analysis. No hypothesis testing of efficacy was planned or performed. Of 140 enrolled patients, 63% had esophageal involvement and 98% were infected with the human immunodeficiency virus (HIV) (median CD4 count, 30/mm(3)). A modestly higher proportion of patients in each of the caspofungin groups (74 to 91%) achieved favorable responses compared to amphotericin B recipients (63%), but there was considerable overlap in the 95% confidence intervals surrounding these point estimates. Similar trends were found in the subgroups with esophageal involvement, a history of fluconazole failure, and CD4 counts of < or =50/mm(3). A smaller proportion of patients receiving any dose of caspofungin experienced drug-related adverse events compared to patients given standard doses of conventional amphotericin B (P < 0.01). Caspofungin provided a generally well-tolerated parenteral therapeutic option for HIV-infected patients with oropharyngeal and/or esophageal candidiasis in this study.

Integrity signals

Registry

Crossref · 10.1128/aac.46.2.451-457.2002

Cites

46 of 46 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Practice Guidelines for the Treatment of Candidiasis
Rex, J. H., Walsh, T. J., Sobel, J. D., Filler, S. G., Pappas, P. G., Dismukes, W. E., & Edwards, J. E. (2000) · Clinical Infectious Diseases · doi:10.1086/313749 · Cited by 927
Development of Interpretive Breakpoints for Antifungal Susceptibility Testing: Conceptual Framework and Analysis of In Vitro-In Vivo Correlation Data for Fluconazole, Itraconazole, and Candida Infections
Rex, J. H., Pfaller, M. A., Galgiani, J. N., Bartlett, M. S., Espinel-Ingroff, A., Ghannoum, M. A., Lancaster, M., Odds, F. C., Rinaldi, M. G., Walsh, T. J., et al. (1997) · Clinical Infectious Diseases · doi:10.1093/clinids/24.2.235 · Cited by 855
Epidemiology of Human Immunodeficiency Virus–Associated Opportunistic Infections in the United States in the Era of Highly Active Antiretroviral Therapy
Kaplan, J. E., Hanson, D. L., Dworkin, M. S., Frederick, T., Bertolli, J., Lindegren, M. L., Holmberg, S. D., & Jones, J. L. (2000) · Clinical Infectious Diseases · doi:10.1086/313843 · Cited by 703
Lipid Formulations of Amphotericin B: Recent Progress and Future Directions
Hiemenz, J. W., & Walsh, T. J. (1996) · Clinical Infectious Diseases · doi:10.1093/clinids/22.supplement_2.s133 · Cited by 404
Epidemiology of oral candidiasis in HIV-infected patients: colonization, infection, treatment, and emergence of fluconazole resistance
Sangeorzan, J. A., Bradley, S. F., He, X., Zarins, L. T., Ridenour, G. L., Tiballi, R. N., & Kauffman, C. A. (1994) · The American Journal of Medicine · doi:10.1016/0002-9343(94)90300-x · Cited by 322
International surveillance of blood stream infections due to Candida species in the European SENTRY program: species distribution and antifungal susceptibility including the investigational triazole and echinocandin agents
Pfaller, M. A., Jones, R. N., Doern, G. V., Fluit, A. C., Verhoef, J., Sader, H. S., Messer, S. A., Houston, A. K., Coffman, S. L., & Hollis, R. J. (1999) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/s0732-8893(99)00046-2 · Cited by 264
Emergence of fluconazole-resistant strains of Candida albicans in patients with recurrent oropharyngeal candidosis and human immunodeficiency virus infection
Ruhnke, M., Eigler, A., Tennagen, I., Geiseler, B., Engelmann, E., & Trautmann, M. (1994) · Journal of Clinical Microbiology · doi:10.1128/jcm.32.9.2092-2098.1994 · Cited by 250
Evaluation of the echinocandin antifungal MK-0991 (L-743,872): efficacies in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis
Abruzzo, G. K., Flattery, A. M., Gill, C. J., Kong, L., Smith, J. G., Pikounis, V. B., Balkovec, J. M., Bouffard, A., Dropinski, J. F., Rosen, H., et al. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.11.2333 · Cited by 241
Esophageal infections: Risk factors, presentation, diagnosis, and treatment
Baehr, P. H., & McDonald, G. B. (1994) · Gastroenterology · doi:10.1016/0016-5085(94)90613-0 · Cited by 214
Current and future antifungal therapy: new targets for antifungal agents
Andriole, V. T. (1999) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/44.2.151 · Cited by 191
Outbreak of a Multiresistant Klebsiella pneumoniae Strain in an Intensive Care Unit: Antibiotic Use as Risk Factor for Colonization and Infection
Asensio, Á., Oliver, A., Diego, P. G., Baquero, F., Pérez-Díaz, J. C., Ros, P., Cobo, J., Palacios, M., Lasheras, D., & Cantón, R. (2000) · Clinical Infectious Diseases · doi:10.1086/313590 · Cited by 187
Efficacy of the Echinocandin Caspofungin against Disseminated Aspergillosis and Candidiasis in Cyclophosphamide-Induced Immunosuppressed Mice
Abruzzo, G. K., Gill, C., Flattery, A. M., Kong, L., Leighton, C., Smith, J. G., Pikounis, V. B., Bartizal, K. F., & Rosen, H. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.9.2310-2318.2000 · Cited by 169
In Vitro Susceptibilities of Candida dubliniensis Isolates Tested against the New Triazole and Echinocandin Antifungal Agents
Pfaller, M. A., Messer, S. A., Gee, S. F., Joly, S., Pujol, C., Sullivan, D. J., Coleman, D. C., & Soll, D. R. (1999) · Journal of Clinical Microbiology · doi:10.1128/jcm.37.3.870-872.1999 · Cited by 137
In vitro activity of a new pneumocandin antifungal, L-743,872, against azole-susceptible and -resistant Candida species
Vázquez, J. A., Lynch, M., Boikov, D. A., & Sobel, J. D. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.7.1612 · Cited by 118
Activity of MK-0991 (l-743,872), a new echinocandin, compared with those of LY303366 and four other antifungal agents tested against blood stream isolates of Candida spp.
Marco, F., Pfaller, M. A., Messer, S. A., & Jones, R. N. (1998) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/s0732-8893(98)00050-9 · Cited by 108
Detection and Significance of Fluconazole Resistance in Oropharyngeal Candidiasis in Human Immunodeficiency Virus-Infected Patients
Revankar, S. G., Kirkpatrick, W. R., Mcatee, R. K., Dib, O. P., Fothergill, A. W., Redding, S. W., Rinaldi, M. G., & Patterson, T. F. (1996) · The Journal of Infectious Diseases · doi:10.1093/infdis/174.4.821 · Cited by 108
Comparison of the in vitro activities of the echinocandin LY303366, the pneumocandin MK-0991, and fluconazole against Candida species and Cryptococcus neoformans
Krishnarao, T. V., & Galgiani, J. N. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.9.1957 · Cited by 102
Clinically Significant Mucosal Candidiasis Resistant to Fluconazole Treatment in Patients with AIDS
Newman, S. L., Flanigan, T., Fisher, A., Rinaldi, M. G., Stein, M. D., & Vigilante, K. C. (1994) · Clinical Infectious Diseases · doi:10.1093/clinids/19.4.684 · Cited by 97
In vitro activity of itraconazole against fluconazole-susceptible and -resistant Candida albicans isolates from oral cavities of patients infected with human immunodeficiency virus
Barchiesi, F., Colombo, A. L., McGough, D. A., Fothergill, A. W., & Rinaldi, M. G. (1994) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.38.7.1530 · Cited by 88
Itraconazole cyclodextrin solution for fluconazole-refractory oropharyngeal candidiasis in AIDS: correlation of clinical response with in vitro susceptibility
Phillips, P., Zemcov, J., Mahmood, W., Montaner, J. S. G., Craib, K., & Clarke, A. M. (1996) · AIDS · doi:10.1097/00002030-199610000-00009 · Cited by 88
Does Long-Term Itraconazole Prophylaxis Result in In Vitro Azole Resistance in Mucosal Candida albicans Isolates from Persons with Advanced Human Immunodeficiency Virus Infection?
Goldman, M., Cloud, G. A., Smedema, M. L., LeMonte, A. M., Connolly, P., McKinsey, D. S., Kauffman, C. A., Moskovitz, B. L., & Wheat, L. J. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.6.1585-1587.2000 · Cited by 88
Treatment of Fluconazole-Refractory Oropharyngeal Candidiasis with Itraconazole Oral Solution in HIV-Positive Patients
Saag, M. S., Fessel, W. J., Kaufman, C. A., Merrill, K. W., Ward, D. J., Moskovitz, B. L., Thomas, C., Oleka, N., Guarnieri, J. A., Lee, J., et al. (1999) · AIDS Research and Human Retroviruses · doi:10.1089/088922299309919 · Cited by 79
Refractory Mucosal Candidiasis in Patients with Human Immunodeficiency Virus Infection
Fichtenbaum, C. J., & Powderly, W. G. (1998) · Clinical Infectious Diseases · doi:10.1086/514571 · Cited by 74
In Vitro Activity of the New Echinocandin Antifungal, MK-0991, against Common and Uncommon Clinical Isolates of Candida Species
Barchiesi, F., Schimizzi, A. M., Fothergill, A. W., Scalise, G., & Rinaldi, M. G. (1999) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/pl00015011 · Cited by 74
Treatment of murine Candida krusei or Candida glabrata infection with L-743,872
Graybill, J. R., Bocanegra, R. A., Luther, M., Fothergill, A. W., & Rinaldi, M. J. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.9.1937 · Cited by 68
Treatment of murine disseminated candidiasis with L-743,872
Graybill, J. R., Najvar, L. K., Luther, M. F., & Fothergill, A. W. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.8.1775 · Cited by 67
A randomized trial of continuous or intermittent therapy with fluconazole for oropharyngeal candidiasis in HIV-infected patients: clinical outcomes and development of fluconazole resistance
Revankar, S. G., Kirkpatrick, W. R., McAtee, R. K., Dib, O. P., Fothergill, A. W., Redding, S. W., Rinaldi, M. G., Hilsenbeck, S. G., & Patterson, T. F. (1998) · The American Journal of Medicine · doi:10.1016/s0002-9343(98)00137-5 · Cited by 67
Clinical Evaluation and Microbiology of Oropharyngeal Infection Due to Fluconazole‐ResistantCandidain Human Immunodeficiency Virus–Infected Patients
Revankar, S. G., Dib, O. P., Kirkpatrick, W. R., McAtee, R. K., Fothergill, A. W., Rinaldi, M. G., Redding, S. W., & Patterson, T. F. (1998) · Clinical Infectious Diseases · doi:10.1086/513950 · Cited by 66
Fluconazole versus Candida albicans : A Complex Relationship
Graybill, J. R., Montalbo, E. M., Kirkpatrick, W. R., Luther, M. F., Revankar, S. G., & Patterson, T. F. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.11.2938 · Cited by 59
Oropharyngeal yeast flora and fluconazole resistance in HIV-infected patientsreceiving long-term continuous versus intermitent fluconazole therapy
Heald, A. E., Cox, G. M., Schell, W. A., Bartlett, J. A., & Perfect, J. R. (1996) · AIDS · doi:10.1097/00002030-199603000-00004 · Cited by 54
Correlation between In Vitro and In Vivo Antifungal Activities in Experimental Fluconazole-Resistant Oropharyngeal and Esophageal Candidiasis
Walsh, T. J., Gonzalez, C. E., Piscitelli, S. C., Bacher, J. D., Peter, J., Torres, R., Shetty, D., Katsov, V., Kligys, K. R., & Lyman, C. A. (2000) · Journal of Clinical Microbiology · doi:10.1128/jcm.38.6.2369-2373.2000 · Cited by 53
Patterns of Fluconazole Susceptibility in Isolates from Human Immunodeficiency Virus-Infected Patients with Oropharyngeal Candidiasis Due to Candida albicans
Laguna, F., Rodríguez-Tudela, J. L., Martı́nez-Suárez, J. V., Polo, R., Valencia, E., Dı́az-Guerra, T. M., Dronda, F., & Pulido, F. (1997) · Clinical Infectious Diseases · doi:10.1093/clinids/24.2.124 · Cited by 51
Determinants for the development of oropharyngeal colonization or infection by fluconazole-resistant Candida strains in HIV-infected patients
Masiá Canuto, M., Gutiérrez Rodero, F., Ortiz de la Tabla Ducasse, V., Hernández Aguado, I., Martín González, C., Sánchez Sevillano, A., & Martín Hidalgo, A. (2000) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s100960000323 · Cited by 46
In Vitro Activity of the New Echinocandin Antifungal, MK-0991, against Common and Uncommon Clinical Isolates of
Barchiesi, F., Schimizzi, A. M., Fothergill, A. W., Scalise, G., & Rinaldi, M. G. (1999) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s100960050283 · Cited by 43
Itraconazol‐Suspension in der Behandlung HIV‐infizierter Patienten mit Fluconazol‐resistenter oropharyngealer Candida‐Infektion und Soorösophagitis
Eichel, M., Just‐Nübling, G., Helm, E. B., & Stille, W. (1996) · Mycoses · doi:10.1111/j.1439-0507.1996.tb00514.x · Cited by 41
In vitro activities of semisynthetic pneumocandin L-733,560 against fluconazole-resistant and -susceptible Candida albicans isolates
Martı́nez-Suárez, J. V., & Rodríguez-Tudela, J. L. (1996) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.40.5.1277 · Cited by 36
Patterns of in vitro activity of itraconazole and imidazole antifungal agents against Candida albicans with decreased susceptibility to fluconazole from Spain
Martı́nez-Suárez, J. V., & Rodríguez-Tudela, J. L. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.7.1512 · Cited by 35
The natural history of esophageal candidiasis after successful treatment in patients with AIDS
Laine, L. (1994) · Gastroenterology · doi:10.1016/0016-5085(94)90122-8 · Cited by 33
Amphotericin B oral suspension for fluconazole-refractory oral candidiasis in persons with HIV infection
Fichtenbaum, C. J., Zackin, R. A., Rajicic, N., Powderly, W. G., Wheat, L. J., & Zingman, B. S. (2000) · AIDS · doi:10.1097/00002030-200005050-00011 · Cited by 33
Fluconazole Suspension for Oropharyngeal Candidiasis Unresponsive to Tablets
Martins, M. D., & Rex, J. H. (1997) · Annals of Internal Medicine · doi:10.7326/0003-4819-126-4-199702150-00020 · Cited by 28
Esophageal candidiasis in AIDS
Lalor, E., & Rabeneck, L. (1991) · Digestive Diseases and Sciences · doi:10.1007/bf01318196 · Cited by 15
Failure of All Antifungal Therapy for Infection Due toCandida albicans. A New AIDS‐Related Problem?
Landman, D., Saurina, G., & Quale, J. M. (1998) · Clinical Infectious Diseases · doi:10.1086/516287 · Cited by 15
Response to fluconazole by 23 patients with human immunodeficiency virus infection and oral candidiasis: pharmacological and mycological factors
Lacassin, F., Damond, F., Chochillon, C., Longuet, P., Bras, J. L., Vildé, J., & Leport, C. (1996) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.40.8.1961 · Cited by 13
Treatment of Thrush with Itraconazole Solution: Evidence for Topical Effect
Mascareñas, C. A., Hardin, T. C., Pennick, G. J., Rinaldi, M. G., & Graybill, J. R. (1998) · Clinical Infectious Diseases · doi:10.1086/598361 · Cited by 10
Fluconazole Orally Dispersible Tablets for the Treatment of Patients with Oropharyngeal Candidiasis
Vandercam, B., Gibbs, D., Valtonen, M., Jäger, H., & Armignacco, O. (1998) · Journal of International Medical Research · doi:10.1177/030006059802600406 · Cited by 5
Visceral Leishmaniasis in Southern Sudan
Nishioka, S. D. A. (1997) · Annals of Internal Medicine · doi:10.7326/0003-4819-126-4-199702150-00018 · Cited by 2

Sorted by citations

Guidelines for Treatment of Candidiasis
Pappas, P. G., Rex, J. H., Sobel, J. D., Filler, S. G., Dismukes, W. E., Walsh, T. J., & Edwards, J. E. (2004) · Clinical Infectious Diseases · doi:10.1086/380796 · Cited by 1,440
Comparison of Caspofungin and Amphotericin B for Invasive Candidiasis
Mora-Duarte, J., Betts, R., Rotstein, C., Colombo, A. L., Thompson-Moya, L., Smietana, J., Lupinacci, R., Sable, C., Kartsonis, N., & Perfect, J. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021585 · Cited by 1,380
Self-citation
Echinocandin antifungal drugs
Denning, D. W. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14472-8 · Cited by 1,131
Caspofungin versus Liposomal Amphotericin B for Empirical Antifungal Therapy in Patients with Persistent Fever and Neutropenia
Walsh, T. J., Teppler, H., Donowitz, G. R., Maertens, J. A., Baden, L. R., Dmoszyńska, A., Cornely, O. A., Bourque, M. R., Lupinacci, R. J., Sable, C. A., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040446 · Cited by 907
Self-citation
Efficacy and Safety of Caspofungin for Treatment of Invasive Aspergillosis in Patients Refractory to or Intolerant of Conventional Antifungal Therapy
Maertens, J., RAAD, I. I., Petrikkos, G. L., Boogaerts, M., Selleslag, D., Petersen, F. B., Sable, C. A., Kartsonis, N. A., Ngai, A. L., Taylor, A., et al. (2004) · Clinical Infectious Diseases · doi:10.1086/423381 · Cited by 651
Self-citation

See all 254

Authors: Arathoon, E. G., Gotuzzo, E., Noriega, L. M., Berman, R. S., DiNubile, M. J., & Sable, C. A.
Affiliations: Hospital General San Juan de Dios (GT)
Hospital Nacional Cayetano Heredia (PE)
Complejo Asistencial Sótero del Río (CL)
Merck Research Laboratories, West Point, Pennsylvania
Corresponding author: DiNubile, Mark J.
ORCID: Arathoon, Eduardo G.
Gotuzzo, Eduardo
Venue: Antimicrobial Agents and Chemotherapy
Publisher: American Society for Microbiology
Published: 2002-02
Volume: 46
Issue: 2
Pages: 451-457
ISSN: 0066-4804 (ISSN-L)
1098-6596
DOI: 10.1128/aac.46.2.451-457.2002
PMC: PMC127070
OpenAlex: W2156228013
Cited by: 254
References: 46
Citations by year: 2026: 1 · 2025: 2 · 2024: 2 · 2023: 1 · 2022: 1 · 2021: 3 · 2020: 6 · 2019: 1 · 2018: 2 · 2017: 4 · 2016: 1 · 2015: 8 · 2014: 8 · 2013: 4 · 2012: 7
FWCI: 18.98
Type: journal article
Language: en
Open access: green
europepmc.org
Licence: journals.asm.org/non-commercial-tdm-license (tdm)
Locations: Antimicrobial Agents and Chemotherapy (publishedVersion)
Europe PMC (PubMed Central) (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
Health Sciences › Dentistry › General Dentistry › HIV/AIDS oral health manifestations
Keywords: caspofungin, amphotericin B, oropharyngeal candidiasis, esophageal candidiasis, HIV infection, CD4 count, drug safety and tolerability, dose-ranging
MeSH terms: Caspofungin, Adolescent, Adult, Aged, Amphotericin B, Anti-Bacterial Agents, Antifungal Agents, Candidiasis, Double-Blind Method, Drug Tolerance, Esophageal Diseases, Female, Humans, Male, Middle Aged, Peptides, Peptides, Cyclic, Pharyngeal Diseases, Treatment Outcome, Echinocandins, Lipopeptides

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Randomized, Double-Blind, Multicenter Study of Caspofungin versus Amphotericin B for Treatment of Oropharyngeal and Esophageal Candidiases

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks